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Abstract
Background: Men with prostate cancer are often challenged to choose between conservative management and
a range of available treatment options each carrying varying risks and benefits. The trade-offs are between an
improved life-expectancy with treatment accompanied by important risks such as urinary incontinence and
erectile dysfunction. Previous studies of preference elicitation for prostate cancer treatment have found
considerable heterogeneity in individuals' preferences for health states given similar treatments and clinical risks.
Methods: Using latent class mixture model (LCA), we first sought to understand if there are unique patterns of
heterogeneity or subgroups of individuals based on their prostate cancer treatment utilities (calculated time
trade-off utilities for various health states) and if such unique subgroups exist, what demographic and urological
variables may predict membership in these subgroups.
Results: The sample (N = 244) included men with prostate cancer (n = 188) and men at-risk for disease (n = 56).
The sample was predominantly white (77%), with mean age of 60 years (SD ± 9.5). Most (85.9%) were married
or living with a significant other. Using LCA, a three class solution yielded the best model evidenced by the
smallest Bayesian Information Criterion (BIC), substantial reduction in BIC from a 2-class solution, and Lo-
Mendell-Rubin significance of < .001. The three identified clusters were named high-traders (n = 31), low-traders (n
= 116), and no-traders (n = 97). High-traders were more likely to trade survival time associated with treatment to
avoid potential risks of treatment. Low-traders and were less likely to trade survival time and accepted risks of
treatment. The no-traders were likely to make no trade-offs in any direction favouring the status quo. There was
significant difference among the clusters in the importance of sexual activity (Pearson's χ2 = 16.55, P = 0.002;
Goodman and Kruskal tau = 0.039, P < 0.001). In multinomial logistic regression, the level of importance assigned
to sexual activity remained an independent predictor of class membership. Age and prostate cancer/at-risk status
were not significant factors in the multinomial model.
Conclusion: Most existing utility work is undertaken focusing on how people choose on average. Distinct clusters
of prostate cancer treatment utilities in our sample point to the need for further understanding of subgroups and
need for tailored assessment and interventions.
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Background
The popularization of prostate-specific antigen (PSA)
screening in the United States since the late 1980s has
resulted in the early detection and sometimes over diag-
noses of prostate cancer, which would not otherwise have
been diagnosed within the patients' lifetime[1]. An
increasing number of men are now challenged to choose
between conservative management (watchful waiting)
and a range of available treatment options including rad-
ical prostatectomy, radiation therapy, brachytherapy, and
hormonal therapy, each carrying varying risks and bene-
fits[2]. The trade-offs men face are between an improved
life-expectancy with treatment accompanied by important
risks such as urinary incontinence and erectile dysfunc-
tion. Since little consensus exists on which treatment will
likely produce the best clinical outcomes,[3] the choices
individuals make depend upon their personal appraisals
of the net gains and losses associated with the treatment
in question and the value one places on specific out-
comes. Thus an explicit evaluation of patients' preferences
using valuation techniques is increasingly reported in the
medical decision-making literature.
Time trade-off (TTO) represents the most common scaling
method used for assessing preferences for health states
resulting from prostate cancer treatment[3,4]. TTO
involves matching estimated years of remaining life with
some health impairment to a shorter number of years in
good health. TTO utilities are calculated as the ratio of
time spent in full health to the time spent in a given health
state (i.e., treated but with side effects). A TTO utility is a
value between 0-1; where 0 signifies death and 1 repre-
sents perfect health. If a treatment outcome for erectile
dysfunction carries a utility of 0.85, this means that each
year lived is discounted by 15% for quality-of-life loss due
to erectile dysfunction.
Previous studies of preference elicitation for prostate can-
cer treatment have found considerable heterogeneity in
individuals' preferences for health states even given simi-
lar treatments and clinical risks. For instance, a recent
meta-analysis reporting utilities for prostate cancer health
states found that utilities for severe urinary problems
ranged 0.48-0.96 and severe sexual problem ranged 0.61
to 1.0 across studies[4]. Thus patients with similar disease
and overlapping clinical characteristics may demonstrate
markedly different preferences for treatment outcomes[5].
Some factors have been shown to be associated with sub-
jective preferences for treatment. For instance, age [6-8],
ethnicity[7], marital status[9], education[9], current gen-
eral health [7], and baseline sexual and urological func-
tions[6-8,10] have been shown to be associated with
prostate cancer utilities in previous studies. However, the
findings remain inconsistent in predicting prostate cancer
treatment utilities. Older men have been found to be less
willing to accept the outcome of erectile dysfunction than
younger men[6]. In another study, the willingness to trade
off survival for sexual potency was significantly related to
level of education and marital status but not age, race,
income, current sexual or urinary function, or disease sta-
tus[9]. Further, an integrated review of published studies
on prostate cancer preferences revealed that many of the
existing studies have been conducted with smaller sam-
ples and have employed at-risk patients only[3] represent-
ing trade-offs that may not be pertinent in a patient
population. There remains a need to understand why sub-
groups of patients vary in their willingness to trade when
presented with similar risks and uncertainties.
Latent class cluster analysis (LCA) is a relatively under-
exploited technique in medical decision-making literature
that can allow for the identification of unique subgroups
based on their prostate cancer treatment utilities. LCA is a
valuable method for theoretically important concepts that
are not amenable to perfect measurement or direct obser-
vation. Treatment preferences associated with prostate
cancer are a case in point. While we cannot directly
observe prostate cancer treatment preferences we are likely
to believe that individuals with certain type of preference
structure will chose quality of life over survival gain or vice
versa. LCA is based on the assumption that patterns of
covariation among observed variables are due to each
manifest variable's relationship to an unobserved latent
variable[11]. If such a variable exists, then by studying the
patterns of covariation among the observed variables, we
can understand and characterize the nature of the latent
variable[11].
Unlike traditional clustering (e.g., k means or fuzzy clus-
tering approaches) that typically involves minimizing
within- and maximizing between-cluster variance, cluster
identification using LCA employs a model-based
approach in which the 'probabilities' of class membership
are estimated from model parameters and individuals'
observed scores[12]. Individuals are assumed to belong to
one of a set of k latent classes where the numbers and sizes
of clusters are not known a priori [12]. LCA clustering
approach allows simultaneous examination of several
indicator (dependent) variables, such as utilities for sev-
eral health states, as well as allows for the inclusion of cov-
ariates to identify predictors of class membership. Mixed
measurement levels can be included in the model; thus no
decisions ought to be made about scaling of the observed
variables. No studies to our knowledge have employed
this promising technique to understand heterogeneity in
prostate cancer treatment utilities.
Using a two-step approach, we first sought to understand
if there are unique subgroups of individuals based onBMC Medical Informatics and Decision Making 2009, 9:47 http://www.biomedcentral.com/1472-6947/9/47
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their prostate cancer treatment utilities (calculated TTO
utilities for various health states) and if such unique sub-
groups exist, then what demographic and urological vari-
ables may predict membership in these subgroups.
Methods
Sample and Setting
Data for this study was from a randomized controlled trial
comparing TTO methodology with enhanced TTO (TTO+
visual analogue scale, VAS)[13,14]. The goal of the pri-
mary study was to establish the validity of enhanced TTO
in improving consistency of utility elicitation (i.e., using
the VAS to provide an anchor for the value placed on the
worst possible outcome related to a particular health state,
and referring to that anchor for all other trade-
offs)[13,14]. The sample (N = 244) included men with
prostate cancer (n = 188) and men at-risk (defined below)
for disease (n = 56). Men with prostate cancer were receiv-
ing treatment at Fox Chase Cancer Center (FCCC), one of
the National Cancer Institute designated comprehensive
cancer centers located in the mid-Atlantic region. Men at-
risk were recruited from the Prostate Cancer Risk Assess-
ment Program (PRAP) established by FCCC in 1996 as a
screening clinic and registry for the study of methods for
early detection and factors that predispose to prostate can-
cer [15].
Eligibility for at-risk patients was similar to the criteria for
entry into PRAP, i.e., any man between ages 35-69 years
with at least one first degree relative or at least two second
degree relatives on the same side of the family with the
diagnosis of prostate cancer; African Americans with or
without a first degree relative with prostate cancer; men
who have tested positive for BRCA1. Ineligibility was
based on inability to speak English and cognitive or emo-
tional inability to understand the trade-offs to be made in
the TTO interviews as determined by clinicians. Inclusion
of men with prostate cancer included those with early
stage disease treated at FCCC with curative intent with sur-
gery or radiotherapy, and age was based on PRAP age cri-
teria of 35-69 years.
Recruitment occurred through brochures and through
local radio advertisements. Interviews occurred in the out-
patient department of the FCCC and participants received
$20 for the completion of the TTO interview. Informed
and signed patient consents were obtained by trained
research staff prior to any data collection. The study was
approved by the Institutional Review Board of the Fox
Chase Cancer Center.
Measures
Demographics and Urological History
Demographic data were collected using an investigator-
designed demographic form that collected information
on age, race/ethnicity, education, income, marital status,
and job status. Additional items elicited subjects' sexual
and urological history, i.e., importance of sex for the sub-
ject (very important, somewhat important, unimportant),
ability to have erection (usually able, sometimes a prob-
lem, usually a problem) and problems with urinary leak-
age (never a problem, sometimes a problem, usually a
problem).
Health States and Utility Elicitation
Utilities were elicited using the TTO interview (n = 121)
and the enhanced TTO interview (n = 123). Respondents
were asked to express their preferences among common
health states resulting from the treatment of localized
prostate cancer treatment. There were 4 single states (40%
risk of erectile dysfunction with radiation therapy, RT;
80% risk of erectile dysfunction with radical prostatec-
tomy, RP; 10% risk of incontinence with RT; and 30% risk
of incontinence with RP) and one joint state (40% risk of
erectile dysfunction + 10% risk of incontinence with RT).
Probabilities for risk of health states associated with ther-
apies were derived from an extensive review of the litera-
ture at time (1997) and in consultation with an expert
panel of urologists and radiation oncologists. Subjects
were offered a choice between living a longer period of
time in years with a side-effect versus living shorter peri-
ods of time without side-effects (watchful waiting). Sur-
vival or time without symptoms was presented in
successively shorter increments of time until the subject
was indifferent to the trade.
Statistical Analyses
There were no statistically significant differences in utili-
ties between experimental and control groups or between
men with cancer or those at-risk for developing prostate
cancer, thus data on all subjects were merged for this sec-
ondary analysis. The TTO utilities were calculated as:
Where U = predicted utility, X = time traded and Y = time
horizon.
First, the skewed utility data were transformed into cate-
gories of utility. Trades based on the four single and one
joint health state were transformed into three categories,
i.e., utility between 0 to .49; .50 to .74; and .75 to .99.
Consistent with the suggestion[16] that individuals who
refuse to trade at all represent a unique group, we sepa-
rately included a category of respondents who refused to
trade at all (U = 1.0).
Cluster Identification
Second, we performed a basic latent class mixture model
analysis of utility categories using Mplus version 5.1
UY X =− 11 (/ ) *BMC Medical Informatics and Decision Making 2009, 9:47 http://www.biomedcentral.com/1472-6947/9/47
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(Muthén & Muthén, Los Angeles, CA), employing the Lo-
Mendell-Rubin adjusted test (LMR) [17], Bayesian Infor-
mation Criterion (BIC) [18], and frequency to assess the
performance of alternative models. The idea of "latent"
class clusters is that it is not known what exactly is anchor-
ing these clusters. Thus the statistical identification ofu-
nique clusters using appropriate BIC and LMR/LRT criteria
is significant in itself as it reveals any latent structure to the
data. LMR assesses distribution of likelihood ratio test
(LRT) for k  and  k-1 classes in evaluating appropriate
number of clusters; a small P-value for LMR LRT suggests
that the model with k classes is preferred over k-1
classes[17]. BIC takes into account the number of param-
eters used in model estimation[18] and rewards models
with fewer classes that more accurately reproduce the
data. Smaller BIC values are preferred as they represent
model improvement over larger values.
Cluster Prediction
To predict cluster membership, we first evaluated utility
classes for significant differences in demographics and
urological history using two sample t-tests and ANOVA
models to compare continuous variables and chi-square
statistics to compare categorical variables (SPSS 15.0, Chi-
cago, IL). Subjects' demographic and urological character-
istics found significant at P ≤ 0.2 on bivariate analysis
were included in a multinomial logistic regression model
to predict cluster membership (SPSS version 15.0, Chi-
cago, IL). Model fit was determined using standard-likeli-
hood ratio tests, while the impact of individual model
factors was determined by evaluating log-likelihood ratio
tests and calculating odds ratios (OR) and 95% confi-
dence intervals (CI). A P-value of < 0.05 was predeter-
mined as a cut-off for statistical significance.
Results
The sample (Table 1) was predominantly white (77%),
with a mean age of 60 years (SD ± 9.5). Most (77%) sub-
jects had a diagnosis of prostate cancer, and most (86%)
were married or living with a significant other. Calculated
utilities and categories of utility are reported in Table 2.
Mean utilities ranged from 0.84 (40% risk of erectile dys-
function + 10% risk of incontinence) to 0.95 (10% risk of
incontinence). Unwillingness to make any trade-offs
(TTO U = 1.0) was lowest for the joint state of 40% risk of
erectile dysfunction+10% risk of incontinence (26.6%)
and highest for 10% risk of incontinence (74.5%).
Cluster Identification using Latent Class Mixture Model
Using utility categories as indices of time trade-off, latent
class mixture model analysis revealed several underlying
distributions (Table 3). By evaluating both the LMR test
and BIC several classes or clusters were identified as being
informative. In our analysis, a three class solution yielded
the best model evidenced by the smallest BIC value, sub-
stantial reduction (110.5) in BIC from the 2-class solu-
tion, and LMR significance of < .001 suggesting a
statistically significant improvement in model fit. Thus,
the three cluster solution was chosen for this analysis
(Table 4).
Based on the utility structures, the three clusters were
named  high-traders,  low-traders, and no-traders. A small
group (n = 31) was high-traders; individuals in this cluster
were more likely to trade survival time that is associated
with treatment to avoid potential risks of treatment.
Majority (n = 116) were low-traders; individuals in this
cluster were less likely to trade survival time associated
with treatment and accepted potential risks of treatment.
The no-trade cluster was more likely to have individuals
who were unwilling to make trade-offs in any direction
favouring watchful waiting or status quo (n = 97).
On bivariate analysis, the three clusters did not differ sig-
nificantly in age, ethnicity, education, income, marital sta-
Table 1: Sample Descriptive Characteristics (n = 244)
Variable Mean ± SD or n (%)
Age 60.36 ± 9.5
Self-Identified Race/Ethnicity:
Caucasian 188 (77%)
African American 50 (20.5%)
Other 6 (2.5%)
Prostate Cancer:
At-risk 56 (23%)
Active Disease 188 (77%)
Education: (n = 207)
Less than High School 45 (21.7%)
More than High School 104 (50.2%)
Post Graduate 58 (28%)
Income: (n = 182)
≤ $ 29,000/year 42 (23.1%)
$ 30,000, < $ 75,000/year 81 (44.5%)
≥ $ 75,000/year 59 (32.4%)
Marital Status: (n = 205)
Married/Living with Sig. Other 176 (85.9%)
Not Married 29 (14.1%)
Job Status: (n = 200)
Working 118 (59%)
Not Working 82 (41%)
Sex Important: (n = 243)
Very Important 97 (39.9%)
Somewhat Important 114 (46.9%)
Unimportant 32 (13.2%)
Ability to Have an Erection: (n = 223)
Usually Able 109 (48.9%)
Sometimes a Problem 44 (19.7%)
Usually a Problem 70 (31.4%)
Problems with Urinary Leaking: (n = 242)
Never Have a Problem 179 (74%)
Sometimes Have a Problem 44 (18.2%)
Usually a Problem 19 (7.9%)BMC Medical Informatics and Decision Making 2009, 9:47 http://www.biomedcentral.com/1472-6947/9/47
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tus, employment status, prostate cancer vs. risk of prostate
cancer, ability to have an erection, or urinary leaking.
There were, however, significant differences in the impor-
tance of sexual activity (Pearson's χ2 = 16.55, P = 0.002;
Goodman and Kruskal tau = 0.039, P < 0.001). That is,
high-traders were more likely to find sex very important,
and low-traders were more likely to find sex unimportant.
Prediction of Cluster Membership
In combination, age, race/ethnicity, history of prostate
cancer and the importance of sexual activity were signifi-
cant in explaining likelihood of class membership (χ2 =
25.7812, P = 0.004). These variables were included in a
multinomial logistic regression model (Table 5). Race/
ethnicity and level of importance assigned to sexual activ-
ity were independent predictors of class membership.
Non-white subjects were less likely to be low-traders than
no-traders (OR 0.409) and more likely to be high-traders
than low-traders (OR 3.222). Subjects who indicated that
sexual activity was very important were much more likely
to be high-traders (OR 7.063) than no-traders, and low-trad-
ers  than no-traders  (OR 4.506). Subjects who indicated
that "sexual activity was somewhat important" were also
much more likely to be low-traders than no-traders (OR
4.377). Age and diagnosis of prostate cancer were not sig-
nificant factors in the multinomial model.
Cluster Membership Uncertainty
It is important to note that in latent class analysis, class
membership is not determined with certainty for each
individual; rather each individual has a probability of
belonging to one of the latent classes. Thus class member-
ship uncertainty should be taken into account in studying
Table 2: Sample TTO Utilities/Categories of Utility
Utility Mean (SD) (IQR) or n (%)
40% Chance of Erectile Dysfunction** .9156 (.146) (.857 to 1.0)
No-trade 137 (56.4%)
.75 to .99 82 (33.7%)
.50 to .74 19 (7.8%)
Up to .49 5 (2.1%)
80% Chance of Erectile Dysfunction* .8636 (.187) (.786 to 1.0)
No-trade 94 (38.7%)
.75 to .99 108 (44.4%)
.50 to .74 30 (12.3%)
Up to .49 11 (4.5%)
10% Chance of Incontinence** .9544 (.120) (.929 to 1.0)
No-trade 181 (74.5%)
.75 to .99 52 (21.4%)
.50 to .74 7 (2.9%)
Up to .49 3 (1.2%)
30% Chance of Incontinence* .8831 (.186) (.857 to 1.0)
No-trade 114 (47.7%)
.75 to .99 92 (38.5%)
.50 to .74 23 (9.6%)
Up to .49 10 (4.2%)
40% Chance of Erectile Dysfunction + 10% Chance of Incontinence** .8358 (.196) (.757 to 1.0)
No-trade 65 (26.6%)
.75 to .99 133 (54.5%)
.50 to .74 32 (13.1%)
Up to .49 14 (5.7%)
TTO = time trade-off
** Risk associated with Radiation Therapy
*Risk associated with Radical Prostatectomy
Table 3: Latent Class Cluster Models of Prostate Cancer 
Treatment Utilities
Classes LMR Test P BIC
2 320.7 < .0005 2266.2
3 196.2 < .0001 2155.7
4 59.7 .007 2183.3
5 53.7 .27 2216.8
BIC = Bayesian Information Criteria
LMR = Lo-Mendell-Rubin Adjusted TestBMC Medical Informatics and Decision Making 2009, 9:47 http://www.biomedcentral.com/1472-6947/9/47
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the association of patient characteristics with the latent
classes [19]. Rigorous analytic techniques have been
developed to account for bias that may result from mod-
erate to substantial uncertainty derived from latent class
analysis [19]. Based on our data, the median probability
of being classified in class I (high-traders) for patients in
class I was 1.000 with an inter-quartile range of .996 to
1.000. Eighty five percent of patients in this class had a
probability of being in this class of .95 or above, and all
but 2 had a probability of being in this class less than .80.
The median probability of being classified in class II (low-
traders) for patients in class II was .995 with an inter-quar-
Table 4: Cluster Identification Using Latent Class Mixture Model Analysis
Clusters† High-traders n = 31
n (%)
Low-traders n = 116
n (%)
No-traders n = 97
n (%)
Utilities
40% Chance of Erectile Dysfunction**
No-trade 4 (12.90) 38 (32.76) 95 (97.94)
.75 to .99 5 (16.13) 76 (65.52) 1 (1.03)
.50 to .74 17(54.84) 2 (1.72) 0 (0.00)
Up to .49 5 (16.13) 0 (0.00) 0 (0.00)
80% Chance of Erectile Dysfunction*
No-trade 0 (0.00) 17 (14.66) 77 (79.38)
.75 to .99 7 (22.58) 82 (70.69) 19 (19.58)
.50 to .74 13 (41.94) 17 (14.66) 0 (0.00)
Up to .49 11 (35.48) 0 (0.00) 0 (0.00)
10% Chance of Incontinence**
No-trade 9 (29.03) 75 (64.66) 97 (100)
.75 to .99 11 (35.48) 41 (35.34) 0 (0.00)
.50 to .74 7 (22.58) 0 (0.00) 0 (0.00)
Up to .49 3 (9.68) 0 (0.00) 0 (0.00)
30% Chance of Incontinence*
No-trade 2 (6.54) 22 (18.97) 90 (92.78)
.75 to .99 3 (9.68) 87 (75.00) 2 (2.06)
.50 to .74 16 (51.61) 4 (3.45) 3 (3.09)
Up to .49 9 (29.03) 1 (0.86) 0 (0.00)
40% Chance of Erectile Dysfunction + 10% Chance of Incontinence**
No-trade 1 (3.23) 7 (6.03) 57 (58.76)
.75 to .99 1 (3.23) 101 (87.07) 31 (31.96)
.50 to .74 17 (54.84) 8 (6.90) 7 (7.22)
Up to .49 12 (38.71) 0 (0.00) 2 (2.06)
†P <.0001(based on Bayesian Information Criteria & Lo-Mendell-Rubin Adjusted Test (see Table 3)
** Risk associated with Radiation Therapy
*Risk associated with Radical Prostatectomy.
Table 5: Multinomial Logistic Regression Results for Latent Classes of Prostate Cancer Utilities
Covariate High- vs. No-traders
OR (95% CI)
Low- vs. No-traders
OR (95% CI)
High- vs. Low-traders
OR (95% CI)
Age 1.046 (0.982 to 1.113) 1.021 (0.979 to 1.064) 1.025 (0.964 to 1.089)
Non-white
White (reference)
1.319 (0.444 to 3.921) 0.409 (0.182 to 0.920)* 3.222 (1.071 to 9.694)*
Men with prostate cancer
Men at-risk (reference)
0.787 (0.181 to 3.411) 0.460 (0.170 to 1.245) 1.711 (0.411 to 7.126)
Sex very important
Sex unimportant (reference)
7.063 (1.413 to 35.301)* 4.506 (1.705 to 11.910)** 1.568 (0.291 to 8.443)
Sex somewhat important
Sex unimportant (reference)
3.052 (0.607 to 15.337) 4.377 (1.745 to 10.981)** 0.697 (0.128 to 3.800)
*= P < 0.05; **= P < 0.01; CI = confidence interval; OR = odds ratioBMC Medical Informatics and Decision Making 2009, 9:47 http://www.biomedcentral.com/1472-6947/9/47
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tile range of .968 to .999. Eighty five percent of patients in
this class had a probability of being in this class of .95 or
above and 10% had a probability less than .80. The
median probability of being classified in class III (no-trad-
ers) for patients in class III was .999 with an inter-quartile
range of .997 to 1.000. Eighty five percent of patients in
this class had a probability of being in this class of .95 or
above and 10% had a probability less than .80. Thus, with
so few cases with moderate and none with substantial
uncertainty with this particular 3 class solution, we
believe there is limited bias derived from selecting the
most likely cluster membership for each patient case and
our methodological approach of studying the association
of individual patient characteristics with these latent
classes.
Discussion
Previous studies have identified heterogeneity in treat-
ment preferences related to prostate cancer. We used LCA
to characterize heterogeneity previously reported to
understand if there are unique subgroups of individuals
based on their observed TTO utilities. LCA is a 'person-
centered' rather than variable-centered approach to
understanding heterogeneity within the data [20]. While
based on aggregatedata onTTO utilitiespresented in Table
2, we know that there is heterogeneity in preferences but
LCA offers little more insight about how subgroups of
people make choices. For instance, clusters analysis (Table
4) tells us that heterogeneity is not based on 'risk' for 'high-
traders' and 'no-traders'. Majority of the 31 people classi-
fied as high-traders traded high across health states regard-
less of amount (TTO utility) or type of risk (erectile
dysfunction versus incontinence). Similarly, majority of
the 97 people identified as no-traders were likely to choose
status quo across risk categories regardless of type and
amount of risk presented. This may mean that people in
these two categories trade based on personal characteris-
tics rather than risks presented, which raise questions
about the theory driven hypothesis that people trade
based on risks presented, i.e., people are risk-averse in the
domain of gains and risk-seeking in the domain of losses
[21].
Thus theheuristic clusters identified may aid in hypothesis
generation such as, high-traders (those who trade life years
to avoid risk of treatment), may be more risk averse, and
may seek to enroll less in curative treatments or clinical
trials with known or unknown risks. From a methodolog-
ical standpoint, individuals in both high-trade and no-trade
categories may respond less to interventionsdesigned to
improve logical trade-offs. Further, from methodological
standpoint, our findings of cluster identification also offer
insights about what level of risk may be meaningfully
interpreted by the participants while completing a TTO
task. For instance, majority of individuals across the three
clusters traded between no-trade to low-trade in the risk cat-
egory of 10% chance of incontinence with radiation ther-
apy. Our interpretation is that the risk is so marginal that
participants may have had a hard time appraising it from
the status quo.
With regard to prediction of cluster membership, in our
analysis of a broad range of utilities of patients with pros-
tate cancer and those at-risk, we find that sexual impor-
tance is a strong determinant of utilities in this patient
population. That is, when compared to patients who
found sex unimportant, patients who reported sexual
activity as being very important were seven times as likely
to trade life associated with treatment to avoid risks of
treatment (erectile dysfunction and incontinence). Our
strong finding is in contrast with Singer et al., who found
that the reported willingness to trade-off survival for sex-
ual potency was not related to interest in sex or frequency
of sexual intercourse[22].
Second, although our sample was not ethnically diverse,
patients who self-identified as non-whites were more
likely to trade at the extremes, as high-traders or no-traders.
These findings may represent within group heterogeneity
and a methodological limitation since we combined Afri-
can Americans and other minorities as non-whites. This
necessitates careful interpretation of this finding. None-
theless, ethnic variations have been found to influence
preferences and outcomes associated with prostate cancer
treatment. In a veterans population newly diagnosed with
localized prostate cancer, Knight et al., found that even
after adjusting for marital status, education level, and
treatment, blacks reported increased difficulty with sexual
interest at 3 and 12 months when compared with
whites[23]. It is likely that race may moderate its effects on
utilities through an interaction with sexual interest. The
finding needs to be confirmed with lager samples of eth-
nically diverse populations.
While we accounted for participants' baseline sexual and
urinary function, cluster typology may also be influenced
by other contextual factors such as risk perceptions and
beliefs about treatment outcomes [5,10]. Future studies of
typology accounting for these important contextual fac-
tors are warranted. Future studies using LCA method may
also undertake more robust analytic techniques that have
been developed to identify class membership uncertainty
[19]. Given that our three cluster solution indicated lim-
ited cluster membership uncertainty, we believe there is
limited bias derived from our present methodological
approach of studying the most likely cluster membership
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Conclusion
Our goal for this study was to understand appropriateness
of LCA as a methodological approach in understanding
unique patterns of heterogeneity in prostate cancer treat-
ment utilities. Our study was limited in that variables
included were those in the dataset collected for the pri-
mary study and did not include variables such as length
and severity of disease, experience with treatment, or
quality of life measures. Further, we did not contextualize
trading types based on patients' perceptions about treat-
ment efficacy and outcomes. Nevertheless, we demon-
strated that there is a latent structure to prostate cancer
treatment utilities. Most existing utility work is under-
taken with the assumptions that groups under study rep-
resent a "single decision-making unit" [16](p.1073) with
mean utilities representing preferences of individuals in
that group. While the policy-level goal for cost-utility
analysis has been to allocate resources based on how peo-
ple chose on average, such approach stands in contrast
with the current movement towards patient-reported out-
comes focusing on patient-centered, tailored assessment
and care. A consistent shift is needed in the conceptual
and methodological approaches to move the decision sci-
ence away from one-size-fits-all approach.
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